{"Clinical Trial ID": "NCT00559754", "Intervention": ["INTERVENTION 1:", "Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel", "Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on day 1, repeated every 3 weeks for a maximum of 4 cycles, then bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on day 1, repeated every 3 weeks for a maximum of 4 cycles."], "Eligibility": ["Incorporation criteria:", "Women, >=18 years of age;", "\u00b7 Primary HER2-negative breast cancer can work;", "Tumour >2cm in size;", "ECOG Performance Status 0-1.", "- Exclusion criteria:", "Previous treatment for breast cancer;", "A metastatic disease;", "Current or recent use (within 10 days of the first dose of Avastin) of aspirin (>325 mg/day) or full-dose anticoagulants for therapeutic purposes;", "A clinically significant cardiovascular disease."], "Results": ["Performance measures:", "Percentage of participants with a complete pathological response (pCR)", "The anatomopathological study of the surgical element was performed and evaluated using Miller-Payne criteria: 1) the primary tumour was grade 5 (no malignant cells identified at the location of the primary tumour (an inductive in situ carcinoma may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at the surgical element assessment was 0 cm; and 4) the pathological stage of the surgical element tumour was pT0pN0pM0, the stage is not applicable (NA).", "Delay: After week 24 (surgery)", "Results 1:", "Title of the arm/group: Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel", "- Arm/group description: Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on day 1, repeated every 3 weeks for a maximum of 4 cycles.", "Total number of participants analysed: 66", "Type of measurement: Number", "Unit of measure: percentage of participants 24.2 (14.5 to 36.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 13/72 (18.06 per cent)", "Neutrophils/granulocytes * 24/72 (5.56%)", "Mucositis/stomatitis * 22/72 (2.78%)", "Vomiting * 21/72 (1.39%)", "* 6/72 (8.33%)", "\u2022 Infection with the number of normal absolute neutrophils (NACs) or neutrophils of grade 1 or 2 * 21/72 (1.39%)"]}